Inotuzumab Ozogamicin Plus Reduced-Intensity Chemotherapy Active in Untreated Older Patients With ALL
Slideset - The combination of inotuzumab ozogamicin with lower-intensity mini-HCVD chemotherapy in older patients with ALL resulted in a high ORR and low early mortality. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 7, 2016 Category: Hematology Source Type: research
Emerging Predictive and Prognostic Factors for AML
Slideset - In this downloadable slideset, Keith Pratz, MD, reviews the key data regarding novel predictive and prognostic factors for acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 7, 2016 Category: Hematology Source Type: research
Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML
Slideset - ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 7, 2016 Category: Hematology Source Type: research
CAR T-Cell Therapy of B-Cell Acute Lymphoblastic Leukemia
Slideset - In this downloadable slideset, Renier Brentjens, MD, PhD describes the clinical application of CAR T cells and reviews the latest data and optimal management of patients receiving CAR T-cell therapy for ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 7, 2016 Category: Hematology Source Type: research
Diagnosis and Prognosis of Chronic Lymphocytic Leukemia
Slideset - In this downloadable slideset, Thomas J. Kipps, MD, PhD, presents slides examining the diagnosis, evaluation, and prognosis of CLL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
New Developments in Monoclonal Antibody –Based Therapies for ALL
Slideset - In this downloadable slideset, Anthony Stein, MD, reviews the key data and optimal management of patients receiving monoclonal antibody therapy for ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
Managing Otherwise Healthy Patients With Newly Diagnosed CLL
Slideset - In this downloadable slideset, Steven E. Coutre, MD, presents slides discussing the management of otherwise healthy patients with newly diagnosed CLL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
Pediatric-Inspired Therapeutic Approaches for Young Adults and Adults With ALL
Slideset - In this downloadable slideset, Dan Douer, MD, reviews the key data and optimal management of adult patients receiving “pediatric-inspired” regimens for ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
Phase III TOWER Substudy: Blinatumomab Shows Health-Related QoL Benefit vs Chemotherapy in R/R Ph- B-Precursor ALL
Slideset - In this subanalysis of the phase III TOWER study, blinatumomab demonstrated superior health-related QoL vs standard-of-care chemotherapy in patients with R/R Ph- B-Precursor ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
Updates on Frontline Therapy for ALL
Slideset - In this downloadable slideset, Hagop M. Kantarjian, MD, reviews and updates the key data and optimal management of adult patients receiving frontline therapy for ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 6, 2016 Category: Hematology Source Type: research
Managing the Patient With Relapsed or Refractory Chronic Lymphocytic Leukemia
Slideset - In this downloadable slideset, Jeffrey A. Jones, MD, MPH, presents slides examining the management of patients with relapsed/refractory CLL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 5, 2016 Category: Hematology Source Type: research
Addition of Vadastuximab Talirine to 7 + 3 Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial
Slideset - Results from a phase Ib trial combining vadastuximab talirine to 7 + 3 induction therapy suggests deeper and more rapid remissions, without added nonhematologic toxicity, for patients with newly diagnosed AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 5, 2016 Category: Hematology Source Type: research
New Hope for Elderly Patients With AML: A Sneak Peek at ASH 2016
Discussion - Treating elderly patients with AML is particularly challenging. The upcoming ASH conference will include presentations from numerous studies of novel approaches that promise to improve outcomes for these patients. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - November 14, 2016 Category: Hematology Source Type: research
What Is the Optimal Treatment for Patients With Relapsed del(17p) CLL?
Discussion - How do the latest clinical data affect treatment selection for patients with relapsed/refractory CLL and the del(17p) genetic abnormality? (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 31, 2016 Category: Hematology Source Type: research
Chronic Myeloid Leukemia: Managing Patients After Failure of TKI Therapy
Slideset - In this downloadable slideset from the CML Clinical Focus program, Elias Jabbour, MD, provides expert perspective on optimizing treatment choices for patients with chronic myeloid leukemia after failure of 2 or more TKIs. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 28, 2016 Category: Hematology Source Type: research
